The Omnia Medical VBR, a vertebral body replacement system developed by Omnia Medical, Invibio Biomaterial Solutions and JALEX Medical, was granted clearance by the FDA. The single-use system, which comes with PEEK-OPTIMA HA Enhanced polymer, is intended for replacing damaged, unstable or collapsed vertebral body in the thoracolumbar spine.
Cell Design Labs was acquired by Gilead Sciences and Kite, Gilead's cell therapy subsidiary, in a deal worth up to $567 million. Cell's new technology platforms will enhance Gilead's research and development efforts in chimeric antigen receptor T-cell and other cellular therapies.
BGI Genomics will work with Sanguine BioSciences to combine genomic and clinical data that will accelerate patient recruitment for precision medicine clinical trials. The database will help drug manufacturers in recruiting more homogeneous patient cohorts for clinical studies.
An initial public offering brought in $250 million for Denali Therapeutics. The company is developing its lead candidates, DNL201 and DNL151 for Parkinson's disease indication and DNL747 for Alzheimer's disease and amyotrophic lateral sclerosis treatment.
Experts are expecting a global increase of biotech crops through the use of CRISPR gene-editing technology. "What we demonstrated with each of the traits was the ability to use CRISPR to generate new genetic and trait variation that breeders can use to tailor a plant to suit conditions," said scientist Zachary Lippman.
Syngenta will expand its use of its Enogen corn enzyme technology by entering into a collaboration with Green Plains, allowing the use of the corn in ethanol production.
Intuitive Surgical closed a $2 billion buyback of common stock under a $3 billion stock repurchasing deal reached in January after it paid $274 million to Goldman Sachs, according to a filing with the SEC. The remaining share repurchases authorized in the deal amount to $717.5 million after closing.
Medtronic confirmed that it paid an undisclosed amount for Crospon, an Ireland-based company that makes tools for the diagnosis, measurement and treatment of gastrointestinal disorders. The purchase is expected to expand Medtronic's portfolio of products for diagnosing and treating esophageal diseases.
An initial public offering of almost 1.9 million shares was priced by Irvine, Calif.-based Hancock Jaffe Laboratories in hopes of raising about $13 million at the midpoint. The company makes bioprosthetic implants for the treatment of heart valve conditions and chronic deep vein insufficiency and is developing the CoreoGraft coronary artery bypass graft to make spahenous vein or radial artery harvesting unnecessary.